» Articles » PMID: 19701890

A Role for HVEM, but Not Lymphotoxin-beta Receptor, in LIGHT-induced Tumor Cell Death and Chemokine Production

Overview
Journal Eur J Immunol
Date 2009 Aug 25
PMID 19701890
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

The TNF member LIGHT also known as TL4 or TNFSF14) can play a major role in cancer control via its two receptors; it induces tumor cell death through lymphotoxin-beta receptor (LT-betaR) and ligation to the herpes virus entry mediator (HVEM) amplifies the immune response. By studying the effect of LIGHT in the transcriptional profile of a lymphoid malignancy, we found that HVEM, but not LT-betaR, stimulation induces a significant increase in the expression of chemokine genes such as IL-8, and an unexpected upregulation of apoptotic genes. This had functional consequences, since LIGHT, or HVEM mAb, thus far known to costimulate T- and B-cell activation, induced chronic lymphocytic leukemia cell death. Many of the mediators involved were identified here, with an apoptotic pathway as demonstrated by caspases activation, decrease in mitochondrial membrane potential, upregulation of the pro-apoptotic protein Bax, but also a role of TRAIL. Moreover, HVEM induced endogenous TNF-alpha production and TNF-alpha enhanced HVEM-mediated cell death. HVEM function was mainly dependent on LIGHT, since other ligands like HSV-glycoprotein D and B and T lymphocyte attenuator were essentially ineffective. In conclusion, we describe a novel, as yet unknown killing effect of LIGHT through HVEM on a lymphoid malignancy, and combined with induction of chemokine release this may represent an additional tool to boost cancer immunotherapy.

Citing Articles

Herpesvirus Entry Mediator as an Immune Checkpoint Target and a Potential Prognostic Biomarker in Myeloid and Lymphoid Leukemia.

Basingab F, Alzahrani R, Alrofaidi A, Barefah A, Hammad R, Alahdal H Biomolecules. 2024; 14(5).

PMID: 38785930 PMC: 11117912. DOI: 10.3390/biom14050523.


Immune checkpoints and cancer immunotherapies: insights into newly potential receptors and ligands.

Kamali A, Bautista J, Eisenhut M, Hamedifar H Ther Adv Vaccines Immunother. 2023; 11:25151355231192043.

PMID: 37662491 PMC: 10469281. DOI: 10.1177/25151355231192043.


Can we consider soluble herpes virus entry mediator (sHVEM) as a tumor marker?.

Javadzadeh S, Tehrani M, Keykhosravi M, Mohammadian-Amiri R, Amjadi O, Hafezi N Caspian J Intern Med. 2022; 13(4):693-698.

PMID: 36420330 PMC: 9659821. DOI: 10.22088/cjim.13.4.693.


Combination of LIGHT (TNFSF14)-Armed Myxoma Virus Pre-Loaded into ADSCs and Gemcitabine in the Treatment of Experimental Orthotopic Murine Pancreatic Adenocarcinoma.

Jazowiecka-Rakus J, Sochanik A, Hadrys A, Fidyk W, Chmielik E, Rahman M Cancers (Basel). 2022; 14(8).

PMID: 35454928 PMC: 9027757. DOI: 10.3390/cancers14082022.


Systemic Delivery of mLIGHT-Armed Myxoma Virus Is Therapeutic for Later-Stage Syngeneic Murine Lung Metastatic Osteosarcoma.

Christie J, Appel N, Zhang L, Lowe K, Kilbourne J, Daggett-Vondras J Cancers (Basel). 2022; 14(2).

PMID: 35053501 PMC: 8773855. DOI: 10.3390/cancers14020337.